Gilead Sciences, Inc. (GILD)

69.56
0.11 0.16
NASDAQ
Prev Close 69.67
Open 70.00
Day Low/High 69.31 / 70.46
52 Wk Low/High 56.56 / 73.34
Volume 7.73M
Exchange NASDAQ
Shares Outstanding 1254.38B
Market Cap 86.46B
P/E Ratio 68.31
Div & Yield N.A. (N.A)
Gilead Sciences Shares Slide on Leerink Price Target Cut

Gilead Sciences Shares Slide on Leerink Price Target Cut

Shares of Gilead Sciences were lower Wednesday after Leerink cut its price target on the shares.

Biotechs Continue to Lead a Listless Market

Stocks are back to flat to slightly lower overall, but biotechs are up some 1.5% following the announcement from Pfizer of plans to buy Medivation for $14 billion. Gilead Sciences is getting some flak for not pursuing Medivation more heavily, but I ...

Pfizer Is Buying Medivation for $14 Billion

Pfizer Is Buying Medivation for $14 Billion

Pfizer confirmed its $14 billion acquisition of cancer drugmaker Medivation on Monday.

Gilead Draws Buyers as Prospect of Business Divide Rises, Jim Cramer Says

Gilead Draws Buyers as Prospect of Business Divide Rises, Jim Cramer Says

RBC Capital analysts say splitting the company into two distinct businesses would free 'trapped value' on drug treatments.

Watch Gilead for Buying Opportunities

Watch Gilead for Buying Opportunities

There is a case for a low already being in place.

Gilead and Teva: Off-the-Charts Cheap

Gilead and Teva: Off-the-Charts Cheap

Rarely do investors get to buy these types of quality businesses at such discounted prices.

Cramer: Here's What to Embrace and What to Shun

Cramer: Here's What to Embrace and What to Shun

With enough of earnings season now under our belt, we check out the promising themes and the sectors to avoid.

It's 'All Systems Go' for Biotech

It's 'All Systems Go' for Biotech

The sector seems to be rebounding after tumbling by more than 40%.

Cramer: What Are You Thinking? It Should Be Long Term

Cramer: What Are You Thinking? It Should Be Long Term

That may be the best way to get through the notorious month of August.

Today's Good, Bad and Ugly

"It's not a joke, it's a rope, Tuco. Now I want you to get up there and put your head in that noose. " --Blondie, "The Good, The Bad and The Ugly"  Strange references often jump off of the page as I write my diary and my mind wanders and free-associ...

The Good, The Bad and The Ugly

"There are two kinds of people in the world, my friend: Those with a rope around the neck and the people who have the job of doing the cutting." Tuco The Ugly, The Good, The Bad and The Ugly Strange references often jump off of the page as I write m...

Buy Gilead Sciences While It's Wallowing

Buy Gilead Sciences While It's Wallowing

It's too cheap for a biotech giant with years of patent protection for key products and great cash flow.

My Takeaways and Observations

Beware of false profits.  Monday's "takeaway." Radian Group was up a second day in a row after a nice, 25%-plus run. Thank you, Barron's.  My Trade of the Week, long SPDR S&P 500 ETF puts. Here's why...  My take on the technicals. A deeper dive into...

Jim Cramer Likes UTX, Says Gilead Has Peaked, Sees a Bottom for Oil

Jim Cramer Likes UTX, Says Gilead Has Peaked, Sees a Bottom for Oil

United Technologies is taking share from competitors like General Electirc.

Cramer: Winners and Losers in the Earnings Game

Cramer: Winners and Losers in the Earnings Game

Good enough, tied with a good story, is pushing post-earnings bumps today.

Trade of the Week: Long SPY Puts

Let's make August $217 monthly puts of the SPDR S&P 500 ETF our Trade of the Week. These puts closed at $2.50 yesterday, and this is a bearish bet. There are several reasons why I feel stocks could decline over the near term, including: Continuing O...

Beware of False Profits

"Beware of false prophets, who come to you in sheep's clothing but inwardly are ravenous wolves." -- Matthew 7:15 I try to exclude personal experiences from my diary and only include observations related to the markets. But I have to start the morni...

Cramer: For Texas Instruments and Gilead, It's all About Trajectory

Cramer: For Texas Instruments and Gilead, It's all About Trajectory

One is rising on a minor sales bump while the other is falling despite solid results; and here is why.

Gilead estimates, target cut at Leerink

Rev's Forum: A Hard Market to Embrace

Rev's Forum: A Hard Market to Embrace

With chaos blaring in the headlines, market players simple shrug.

Expect an Interesting Week Ahead

It has been great standing in for Doug Kass today. Evidently, Monday has a more engaged investor audience than my usual Friday beat. There were more than 200 comments today in a very lively back-and-forth session. It made what was a dull trading day...

Where Is the Insider Buying?

The market is off its worst levels of the day. Big biotech and biopharma are providing strength today, with Biogen , Gilead Sciences and Mylan all sporting solid gains in a down market. Energy has made a bit of a comeback, but still is down nearly 2...

Market's Lower, But These 3 Stocks Aren't

The market is starting to spot larger losses. The energy sector is the big loser so far. With oil heading down to $43 a barrel, the segment is down more than 2% on the day. Despite what many regarded as a divided Republican National Convention, GOP ...

Is Timeframe on Your Side?

Is Timeframe on Your Side?

Earnings reports will test the timeframe mettle for some investors and traders.

Gilead Readying for Earnings Report

Gilead Readying for Earnings Report

The biopharmaceutical giant is getting ready to report its second-quarter results, which are set to be released after Monday's close.

I'm Bullish on Biotechs

The market continues to trade lower as we late morning, with Tobira Therapeutics serving as the "disaster du jour" in the small-cap biotech space. This stock is trading down some 60% after its midstage compound targeting non-alcoholic steatohepatiti...

Morning Movers: YHOO, VZ, DHR, GILD

Morning Movers: YHOO, VZ, DHR, GILD

Verizon won the competitive bidding process for Yahoo and will pay the company $4.8 billion for its internet properties.

What to Watch This Week: Apple, Facebook, Alphabet Report Earnings; Federal Reserve Meeting

What to Watch This Week: Apple, Facebook, Alphabet Report Earnings; Federal Reserve Meeting

A slew of corporate earnings and closely watched Federal Reserve meeting are in focus for the week of July 25.

4 Small-Cap Biotechs With Big Stories to Tell

4 Small-Cap Biotechs With Big Stories to Tell

Watch these names as stability returns to the sector.